Výsledky vyhledávání

Akademický článek

L1 chimeric transcripts are expressed in healthy brain and their deregulation in glioma follows that of their host locus.

Autor: Pinson ME; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Court F; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Masson A; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Renaud Y; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Fantini A; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Bacoeur-Ouzillou O; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Barriere M; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Pereira B; Biostatistics Department, Délégation à la Recherche Clinique et à l'Innovation, Clermont-Ferrand Hospital, Clermont-Ferrand 63003, France., Guichet PO; Cancer Biology Department, CHU de Poitiers, Poitiers 86021, France., Chautard E; Université Clermont Auvergne, INSERM, U1240 IMoST, Clermont-Ferrand 63011, France.; Pathology Department, Centre Jean PERRIN, Clermont-Ferrand 63011, France., Karayan-Tapon L; Cancer Biology Department, CHU de Poitiers, Poitiers 86021, France.; INSERM, U1084, Poitiers 86021, France.; Université de Poitiers, Poitiers 86000, France., Verrelle P; INSERM, U1196 CNRS UMR9187, Curie Institute, Orsay 91405, France.; Radiotherapy Department, Curie Institute, Paris 75005, France.; Université Clermont Auvergne, Clermont-Ferrand 63000, France., Arnaud P; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France., Vaurs-Barrière C; Université Clermont Auvergne, CNRS, Inserm, iGReD, Clermont-Ferrand F-63000, France.

Publikováno v: Human molecular genetics [Hum Mol Genet] 2022 Aug 17; Vol. 31 (15), pp. 2606-2622.

Zobrazit plný text záznamu

Akademický článek

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.

Autor: Bonnevaux H; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Guerif S; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Albrecht J; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Jouannot E; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., De Gallier T; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Beil C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Lange C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Leuschner WD; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Schneider M; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Lemoine C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Caron A; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Amara C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Barrière C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Siavellis J; Hopitaux Universitaires Paris Ile De France Ouest, Université Versailles Saint Quentin, Paris, France., Bardet V; Hopitaux Universitaires Paris Ile De France Ouest, Université Versailles Saint Quentin, Paris, France., Luna E; Sanofi Pasteur VaxDesign, Orlando, FL, USA., Agrawal P; Sanofi Pasteur VaxDesign, Orlando, FL, USA., Drake DR; Sanofi Pasteur VaxDesign, Orlando, FL, USA., Rao E; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Wonerow P; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Carrez C; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Blanc V; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Hsu K; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Wiederschain D; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Fraenkel PG; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA., Virone-Oddos A; Sanofi R&D, Vitry-sur-Seine, France; Frankfurt, Germany; and Cambridge, MA, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2021 Aug 31; Vol. 10 (1), pp. 1945803. Date of Electronic Publication: 2021 Aug 31 (Print Publication: 2021).

Zobrazit plný text záznamu

Akademický článek

Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.

Autor: Le Boiteux E; CNRS, Inserm, GReD, Université Clermont Auvergne, Clermont-Ferrand, France., Court F; CNRS, Inserm, GReD, Université Clermont Auvergne, Clermont-Ferrand, France., Guichet PO; INSERM-U1084, Poitiers, France.; Poitiers University, France.; Department of Cancer Biology, Poitiers Hospital, France., Vaurs-Barrière C; CNRS, Inserm, GReD, Université Clermont Auvergne, Clermont-Ferrand, France., Vaillant I; CNRS, Inserm, GReD, Université Clermont Auvergne, Clermont-Ferrand, France., Chautard E; Pathology Department, Jean Perrin Center, Clermont-Ferrand, France.; INSERM, U1240 IMoST, Université Clermont Auvergne, Clermont-Ferrand, France., Verrelle P; CIMB, INSERM U1196 CNRS UMR9187, Curie Institute, Orsay, France.; Radiotherapy Department, Curie Institute, Paris, France.; Université Clermont Auvergne, Clermont-Ferrand, France., Costa BM; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, Braga, Portugal.; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal., Karayan-Tapon L; INSERM-U1084, Poitiers, France.; Poitiers University, France.; Department of Cancer Biology, Poitiers Hospital, France., Fogli A; CNRS, Inserm, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.; Biochemistry and Molecular Biology Department, Clermont-Ferrand Hospital, France., Arnaud P; CNRS, Inserm, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.

Publikováno v: Molecular oncology [Mol Oncol] 2021 Aug; Vol. 15 (8), pp. 1995-2010. Date of Electronic Publication: 2021 May 02.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání